Lobbying related to federal legislation and regulations affecting employer-sponsored health coverage, including the Patients Deserve Price Tags Act and other proposals to enhance health care price transparency, employer access to claims and encounter data, and reporting requirements necessary for ERISA plan sponsors to fulfill fiduciary obligations. Lobbying related to reform and oversight of the 340B Drug Pricing Program, including reporting and transparency requirements for covered entities and contract pharmacies, program integrity measures, and policies affecting employer-sponsored health plan costs, biosimilar adoption, and commercial market competition. Lobbying related to hospital price transparency requirements, site-neutral payment policies, anti-competitive contracting practices, and other federal policies intended to improve health care affordability, competition, and transparency for employers and consumers. Lobbying related to implementation and reform of the Independent Dispute Resolution (IDR) process established under the No Surprises Act, including administrative efficiency, compliance, payment determination methodologies, and impacts on employer-sponsored health plans.
2026 · 3rd Quarter (July 1 - Sep 30)
NATIONAL ALLIANCE OF HEALTHCARE PURCHASER COALITIONS
Filed by NATIONAL ALLIANCE OF HEALTHCARE PURCHASER COALITIONS.
Open official filingSource-reported fields
Filing overview
- Type
- 3rd Quarter - Report
- Posted
- Nov 3, 2026
- Income
- Not reported
- Expenses
- $15,000.00
- Filing UUID
- 4a3b7bbe-d400-4a17-871c-33533eff672b
- Termination date
- Not reported
Expense method: A
Literal source text
Lobbying issues and bill citations
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.